AstraZeneca’s immunotherapy drug wins key lung cancer approval … – Nasdaq
Nasdaq |
AstraZeneca's immunotherapy drug wins key lung cancer approval …
Nasdaq LONDON, Feb 17 (Reuters) – AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food … Immunotherapy Drug Wins Key Lung Cancer OK | Newsmax.com UPDATE 2-AstraZeneca's immunotherapy drug wins key lung cancer approval AstraZeneca's cancer therapy Imfinzi gets FDA nod |
